Steady erosion not dramatic plunge likely as Actos faces first generics in Japan
This article was originally published in Scrip
This month's delayed reimbursement price listing of generic products in Japan will include the first such competition to Takeda's big selling oral antidiabetic Actos (pioglitazone), with Sawai and Towa Yakuhin among the leading local firms in the sector set to enter the fray.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.